Dr. Bryan A. Faller, MD

Dr. Faller practices at Missouri Baptist Medical Center in Saint Louis, Missouri, part of BJC Health.

Dr. Faller's NPI, 1790870178, was assigned on October 3, 2006. Dr. Faller graduated from Washington University School of Medicine in 2004. Dr. Faller holds Missouri license 2006002688.

Dr. Faller's primary practice is Missouri Baptist Medical Center, at 3015 N Ballas Rd, Saint Louis, MO 63131 in St. Louis County. The practice phone is (314) 996-5000.

Dr. Faller's primary practice is Missouri Baptist Medical Center in Saint Louis, Missouri, part of BJC Health. Dr. Faller is also affiliated with Barnes-Jewish West County Hospital. The medical group on file is Missouri Baptist Medical Center. Dmand AI also links Dr. Faller to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Faller practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Faller's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Faller is licensed in Missouri.

CMS data shows 1,005 Medicare services from Dr. Faller across 9 procedure codes in 2024, for 277 Medicare patients. Medicare paid $75,016 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 277 Medicare patients who saw Dr. Faller in 2024. The largest group is 65 to 74, with 117 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Faller's median patient age at 75, with 61% women.

In 2024, Dr. Faller wrote 1,486 Medicare Part D claims for 244 patients. 80% of them were for generic drugs. CMS names the drug for 1,137 of them, across 34 drugs with 11 or more claims each, at $2,011,373 in total drug cost. In 2023, CMS named 953 claims across 31 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Faller for performance year 2024, reported as part of a group. Dr. Faller accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 16 papers to Dr. Faller, published from 2011 to 2024. 2021 was the busiest year, with 5. The most frequent topics are Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols and Lung Neoplasms. Dr. Faller has published most often in JAMA Oncol. Dr. Faller's most frequent co-authors are Adedayo A. Onitilo, MD, Toni K. Choueiri, MD and Konstantin Hristov Dragnev, MD.

Dmand AI links Dr. Faller to 10 clinical trials, 5 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Oropharyngeal Neoplasms, Pharyngeal Neoplasms and Adenocarcinoma Of Esophagus. National Cancer Institute (NCI) sponsors the most, 9.

CMS Open Payments shows 621 general payments to Dr. Faller from 75 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 93% of the total. Genentech, Inc. paid the most, $1,357. It also lists 1 research payment totaling $478 in 2025.

Dr. Faller graduated from Washington University School of Medicine in 2004.